Natixis bought a new stake in shares of Novartis AG (NYSE:NVS) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 4,421 shares of the company’s stock, valued at approximately $333,000.

A number of other hedge funds have also added to or reduced their stakes in NVS. Charles Schwab Investment Advisory Inc. bought a new stake in Novartis during the second quarter valued at $297,538,000. Boston Partners increased its stake in Novartis by 106.0% during the second quarter. Boston Partners now owns 5,606,630 shares of the company’s stock valued at $423,525,000 after purchasing an additional 2,885,436 shares during the last quarter. Renaissance Technologies LLC increased its stake in Novartis by 89.3% during the second quarter. Renaissance Technologies LLC now owns 3,856,288 shares of the company’s stock valued at $291,304,000 after purchasing an additional 1,819,590 shares during the last quarter. Summit Trail Advisors LLC increased its stake in Novartis by 7,896.3% during the first quarter. Summit Trail Advisors LLC now owns 1,483,078 shares of the company’s stock valued at $1,483,000 after purchasing an additional 1,464,531 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in Novartis by 12.8% during the first quarter. Loomis Sayles & Co. L P now owns 7,802,086 shares of the company’s stock valued at $630,799,000 after purchasing an additional 887,198 shares during the last quarter. Hedge funds and other institutional investors own 10.95% of the company’s stock.

Several research firms have weighed in on NVS. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Tuesday, September 18th. BNP Paribas upgraded shares of Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. Exane BNP Paribas upgraded shares of Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. Finally, Citigroup upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 11th. Eleven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Novartis has a consensus rating of “Hold” and a consensus price target of $86.90.

Novartis stock opened at $85.46 on Monday. The stock has a market cap of $198.05 billion, a PE ratio of 17.77, a PEG ratio of 1.79 and a beta of 0.85. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.15 and a quick ratio of 0.89. Novartis AG has a one year low of $72.30 and a one year high of $94.19.

Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.27 by $0.02. The business had revenue of $13.16 billion during the quarter, compared to analyst estimates of $12.93 billion. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.22 earnings per share. equities research analysts predict that Novartis AG will post 5.17 EPS for the current year.

In other news, major shareholder Bioventures Ltd Novartis sold 8,181 shares of the company’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $3.22, for a total transaction of $26,342.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 81,322 shares of company stock valued at $290,796 in the last 90 days. Insiders own 0.01% of the company’s stock.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Featured Article: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.